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tiﬁed this new species. It consists of small non-fermenting
aerobic Gram-negative coccobacilli, with O-shaped morphol-
ogy. The bacterium is catalase- and oxidase-positive. Its
phenotype is identiﬁed by PCR and conﬁrmed with 16S rRNA
gene sequencing. It was identiﬁed for the ﬁrst time in the per-
itoneal ﬂuid in a peritoneal dialysis patient in Pennsylvania1
and subsequently anecdotally identiﬁed in other cases.2 It
mainly affects immunodepressed patients and may cause skin
infections,3 myocarditis,4 arthritis,5 keratitis and corneal graft
rejection.6,7
It is found naturally in soil. Given that our patient had
a small dog, we  thought this could have brought the bacte-
CDCgroup EO-2), a novel bacterial species associated with
human infection. J Clin Microbiol. 2003;41:1289–94.
2. Palamuthusingam D, Tan KS. The ﬁrst case of Paracoccus yeeii
species infection in Australia causing peritonitis in an APD
patient. Nephrology (Carlton). 2014;19:116.
3. Funke G, Frodl R, Sommer H. First comprehensively
documented case of Paracoccus yeei infection in a human. J Clin
Microbiol. 2004;42:3366–8.
4. Schweiger M, Stiegler P, Scarpatetti M, Wasler A, Sereinigg M,
Prenner G, et al. Case of Paracoccus yeei infection documented
in a transplanted heart. Transpl Infect Dis. 2011;13:
200–3.
5. Coifﬁer G, Gougeon A, Albert JD, Le Bars H. Arthritis due to
Paracoccus yeei. Med Mal Infect. 2013;43:254–5.ria to her house, that the patient could have contaminated
herself with it if she failed to comply with strict hand-
6. Courjaret JC, Drancourt M, Hoffart L. Paracoccus yeei keratitis in







decrease in bone resorption of trabecular and cortical bone. Itwashing and it could have passed to the peritoneum during
connection.
The Paracoccus yeei bacterium is sensitive to beta-lactams,
especially aminopenicillins and carbapenems, as well as
third-generation cephalosporins. Intraperitoneal administra-
tion of antibiotics achieves improvement, as there is a higher
concentration of bacteria at the infected site, and easily leads
to eradication of the bacterium.
The course of our patient’s peritonitis was good, with a
gradual drop in leukocytes in the efﬂuent from the time when
she received the culture. Vancomycin was suspended and
treatment was completed with ceftazidime for 14 days.
This bacterium is rarely identiﬁed in clinical samples. Ani-
mals such as a horse8 or, in our case, a dog may be the vehicle
for human contamination.
We believe this to be the ﬁrst reported case of Paracoccus
yeei peritonitis in Spain.
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Dear Editor:Denosumab is a human monoclonal antibody (IgG2) that binds
with great afﬁnity and speciﬁcity to RANKL and blocks activa-
tion of RANK, its receptor, on the surface of osteoclasts and
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is used for the treatment of osteoporosis and is administered
every 6 months.1,2 It is not necessary to adjust the dose in
renal failure, but there is an increased risk of hypocalcaemia.1
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Table 1 – Laboratory data at baseline and over time.
Laboratory parameters Prior to treatment 
Corrected calcium (mg/dl) 9.6
Phosphorus (mg/dl) 5.4 
Alkaline p. (IU/l) 63 
iPTH (pmol/l) 39 
25-OH vit. D (ng/ml) 26 
Creatinine (mg/dl) 3.57 
MDRD (ml/min) 20.69 
We  present the case of a 36-year-old man  with chronic
idney disease due to stage 4 focal and segmental glomeru-
onephritis, who  started with a nephrotic syndrome 3
ears earlier. He had a poor clinical course, with sus-
ained nephrotic syndrome and deterioration of renal
unction, despite receiving treatment with corticosteroids,
yclosporin, mycophenolate and rituximab, with clinical
volution as steroid-resistant nephrotic syndrome. He devel-
ped symptomatic secondary osteoporosis, with signiﬁcant
umbar pain and bone loss documented by densitometry,
nd vertebral compression fractures. He was evaluated by
heumatology, and it was decided to start treatment with
enosumab 60 mg.  At that time, the patient was being
reated with prednisone (10 mg/day), furosemide, chlortali-
one, spironolactone, rosuvastatin, allopurinol, omeprazole
nd paracetamol. In addition, he was receiving 1.2 g of calcium
arbonate with 800 IU of cholecalciferol.
After 3 weeks of ﬁrst dose of denosumab, the patient devel-
ped asymptomatic severe hypocalcaemia, which remained
resent and was even more  severe at week 8. At that time,
holecalciferol was suspended and calcitriol (0.25 mcg/48 h)
nd calcium acetate (500 mg/8 h) were added. At week 15,
erum calcium had returned to normal, but secondary hyper-
arathyroidism with hyperphosphoraemia related to his renal
ailure were observed. Calcitriol was suspended and a non-
alcium chelator (sevelamer carbonate, 2.4 g/day) was added.
t 21 weeks biochemical parameters had improved (Table 1).
he patient was asymptomatic throughout this period despite
evere hypocalcaemia. Lumbar pain improved, but it was
ecided to suspend treatment with denosumab.
This was a young patient with stage 4 chronic kidney
isease (CKD) who had osteoporosis following prolonged
reatment with corticosteroids. Although he previously had
ormal levels of calcium, vitamin D, iPTH and alkaline phos-
hatase, he had probably also developed a bone mineral
isorder associated with this (BMD-CKD).
BMD-CKD is more  complex than osteoporosis. It includes
ll biochemical and skeletal abnormalities and extra-skeletal
alciﬁcations that occur as a result of abnormal mineral
etabolism in CKD. Abnormalities in both remodelling and
ate of remineralisation may occur, resulting in different types
f bone disease (osteitis ﬁbrosa, adynamic bone disease and
steomalacia).3,4 The use of an antiresorptive agent may have different impact on the different types of bone disease, and
ould also have a different impact than in patients without
KD. Inhibition of osteoclast activity by denosumab could
esult in hungry bone syndrome.
There are only few studies on the use of denosumab in the
reatment of osteoporosis that have included patients with
5
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advanced CKD, and these have included a limited number of
patients.5–8 The FREEDOM study excluded patients with stage
5 CKD, and there were very few patients with stage 4 disease to
assess whether the use of denosumab had signiﬁcant beneﬁt.
All reports appear to indicate that there is an increased risk
of hypocalcaemia, and that hypocalcaemia is severe, but the
amount of information is limited and is hard to determine the
severity of hypocalcemia with clear evidence, or to establish
whether this effect is the same in the different types of BMD-
CKD.
Notably, once hypocalcaemia has resolved, there is a
marked increase in PTH, perhaps related to phosphorus reten-
tion due to renal failure which stimulates PTH synthesis and
secretion.
More studies are needed to evaluate the safety of deno-
sumab in CKD, especially in those with a GFR < 30 ml/min, and
in the different forms of BMD-CKD. Until the available evi-
dence of the therapeutic beneﬁt of denosumab in this type of
patient is more  solid, it seems reasonable to assess its indica-
tion on a case-by-case basis and, if the treatment is indicated,
there should be closer clinical follow-up, being alert for symp-
toms of hypocalcaemia and with more  frequent laboratory
testing than in patients with normal renal function.
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Dear Editor:
Peritoneal dialysis is a type of renal replacement ther-
apy that uses the physical and chemical properties of the
peritoneal membrane to perform ultraﬁltration and clear-
ance processes.1–3 One complication of this procedure is
peritonitis,4,5 which is diagnosed with the presence of at least
two out of the three following criteria: a leukocyte count higher
than 100 mm−3, a corresponding clinical picture and microor-
ganisms on a Gram stain.4,5
The International Society for Peritoneal Dialysis recom-
mends management with ﬁrst-generation cephalosporins
for Gram-positive microorganisms and third-generation
cephalosporins for Gram-negative microorganisms.6
It also recommends starting treatment with third-
generation cephalosporins (ceftazidime) and ﬁrst-generation
cephalosporins (cefalotin) by the intraperitoneal route, with
permeation doses of one gram and maintenance doses of
250 mg  every 6 h; however, the response is uncertain.7
Against this background, the aim of this study was to
compare the efﬁcacy of the permeation regime and the main-
tenance regime in patients with peritonitis due to dialysis.
A cohort study was conducted in patients with end-stage
renal disease and peritonitis. The exposure group includedDOI of original article:
http://dx.doi.org/10.1016/j.nefro.2016.02.006.
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patients treated with a permeation regimen (one gram of
ceftazidime/cefalotin q 24 h); the unexposed group included
patients with a maintenance regimen (one gram initially and
250 mg of ceftazidime/cefalotin q 6 h thereafter).Patients with a diagnosis made by cell count were included;
patients with refractory peritonitis, recurrent peritonitis or
cephalosporin allergy were excluded.
The sample (31 per group) was calculated using a percent-
age formula for 2 populations, assuming that the efﬁcacy of
ceftazidime/cefalotin was 60% in the permeation group and
35% in the maintenance group.
Their sociodemographic characteristics, concomitant dis-
eases, modality of dialysis, time on peritoneal dialysis and
time of progression of chronic kidney disease were studied.
Therapeutic efﬁcacy was established through cell counts,
using 99 cells per ﬁeld as a cut-off point, evaluated at 24, 48,
72 and 96 h.
Analysis included percentages, averages, standard devia-
tions, Student’s t-test for independent populations and the
chi-squared test.
Age and gender were similar in the permeation group and
the maintenance group: 48.06 ± 17.79 years and 55.07 ± 12.64
years (p = 0.84); male gender with 65.6% and 62.1%, respec-
tively (p = 0.77). In these groups the prevalence of hypertensionrreal-Ríos E, Galicia-Rodríguez L, Martínez-González L. Eﬁcacia
tazidima/cefalotina en pacientes con peritonitis por diálisis.
